Rationale 5-HT receptor mechanisms have been suggested to mediate improvements in cognition in schizophrenia. Aim The aim of this study was to investigate the involvement of 5-HT receptor mechanisms in sub-chronic phencyclidine (PCP)-induced reversal learning deficits in female rats, a task of relevance to schizophrenia. Methods Adult female hooded Lister rats were trained to perform an operant reversal learning task and then received sub-chronic PCP (2 mg/kg) or vehicle intraperitoneally (i.p.) twice daily for 7 days, followed by 7-day washout. Rats then received an acute dose of the 5-HT 7 receptor antagonist SB-269970A (1.0, 3.0, and 10.0 mg/kg, i.p.) or vehicle. In experiment 2, PCP-treated rats received the selective 5-HT 2C receptor antagonist, SB-243213A acutely (1.0, 3.0, and 10.0 mg/kg, i.p.) or vehicle. In experiment 3, PCP-treated rats received the 5-HT 1A receptor partial agonist, buspirone (0.15625, 0.3125, and 0.625 mg/kg, i.p.) in combination with the selective 5-HT 1A receptor antagonist WAY-100635 (0.3 and 1.0 mg/kg). Results In all experiments, sub-chronic PCP significantly impaired reversal phase performance (P<0.01-0.001), with no effect in the initial phase. SB-269970A at 3.0 and 10.0 mg/kg significantly improved the PCP-induced deficit (P<0.05). SB-243213A also significantly attenuated the deficit at 10 mg/kg (P<0.05). In experiment 3, buspirone attenuated the deficit with significant effects at 0.3125 and 0.625 mg/kg (P<0.05). WAY-100635 at 0.3 and 1.0 mg/kg produced a partial attenuation of buspirone's effect as buspirone (0.3125 mg/kg) in the presence of WAY-100635 did not significantly reverse the PCP-induced deficit. Conclusions These studies implicate the role of 5-HT 7 , 5-HT 2C , and 5-HT 1A receptors in the improvement of cognitive dysfunction of relevance to schizophrenia.
Introduction
Sub-chronic phencyclidine (PCP) dosage regimes used to induce cognitive impairments in rats are believed to mimic those seen in schizophrenia (Javitt and Zukin 1991; Jentsch and Roth 1999) . In our laboratory, we have shown that PCP selectively impairs performance in reversal learning (Abdul-Monim et al. 2006 McLean et al. 2009 ), attentional set-shifting (McLean et al. 2008a) , and novel object recognition (Grayson et al. 2007 ); importantly, these tests are all of relevance to schizophrenia as highlighted by the MATRICS.ucla.edu initiative (Measurement and Treatment Research to Improve Cognition in Schizophrenia), and subsequently the TURNS.ucla.edu program (Treatment Units for Research on Neurocognition and Schizophrenia). Our sub-chronic PCP dosing regime causes reduced density of parvalbumin-immunoreactive neurons in hippocampal regions (Abdul-Monim et al. 2007 ) and levels of brainderived neurotrophic factor messenger RNA in cortical regions (Snigdha et al. 2007 ) in rats. Reductions in GABAergic interneurones in these areas have been found in post-mortem analysis from patients with schizophrenia (Benes et al. 1991; Benes and Berretta 2001; Beasley et al. 2002; Zhang and Reynolds 2002) . We have shown that atypical but not classical antipsychotics can reverse these cognitive deficits; however, in the clinic, there is differing evidence for the efficacy of atypical antipsychotics in improving cognition with the CATIE study (Lieberman 2006; Keefe et al. 2007 ) and the UK Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study ; Lewis et al. 2006) suggesting that antipsychotics actually have a limited effect. Cognitive dysfunction is a core characteristic of schizophrenia (Sullivan et al. 1994; Elvevag and Goldberg 2000; Kuperberg and Heckers 2000) , occurring in 75-85% of patients (Reichenberg et al. 2006) , and is becoming increasingly important as impaired cognition has been implicated in poor long-term functional outcome (Marder and Fenton 2004) which can often persist when other symptoms may be improved with treatment (Gold et al. 1991; Heinrichs 2005) .
The serotonergic system has been strongly implicated in the neurobiology of schizophrenia (for reviews, see Meltzer 1995; Roth et al. 2004 ). Meltzer et al. (1989) defined atypical antipsychotic drugs as having higher affinity for 5-HT 2A receptors than for D 2 receptors. 5-HT 2A receptor antagonists increase dopamine release in the prefrontal cortex (PFC; Ichikawa and Meltzer 1990) . Although atypical antipsychotics such as risperidone and clozapine have high affinity for 5-HT 2A receptors, it is unlikely that this mechanism alone is responsible for their antipsychotic action, as both have been shown to saturate 5-HT 2 receptors at sub-therapeutic doses (Kapur et al. 1999) . In our laboratory, we plan to identify which 5-HT receptors are important for cognition through the use of selective compounds; as part of this work, we have already shown that the 5-HT 2A antagonist, M100.907, is efficacious in improving a sub-chronic PCP-induced deficit in reversal learning .
5-HT 7 receptors have been shown to have a role in learning and memory (Hedlund and Sutcliffe 2004; Thomas and Hagan 2004) . Risperidone and asenapine have high 5-HT 7 receptor affinity (Shahid et al. 2009 ), and we have demonstrated efficacy of asenapine to reverse PCP-induced deficits in our models (Neill et al., submitted) . 5-HT 1A receptor agonism has been suggested to contribute to an atypical antipsychotic drug profile (Protais et al. 1994 ). There are also interactions between 5-HT 2A , 5-HT 2C , and 5-HT 1A receptors (Kapur and Remington 1996; Meltzer 1999 ). Antipsychotics which have been shown to be superior in improving cognition compared to typical antipsychotics in the clinic, including risperidone, olanzapine, and ziprasidone (Harvey et al. 2004; Purdon et al. 2000) have high affinity for the 5-HT 2C receptor (see Miyamoto et al. 2005) . Furthermore, the 5-HT 2C antagonist, SB 242084, has recently been shown to improve serial spatial reversal learning (Boulougouris et al. 2008) , supporting a role for 5-HT 2C receptors in cognition.
The aim of this study was to elucidate the 5-HT receptor mechanisms involved in the PCP-induced reversal learning deficit; by using selective compounds, we also intend to further enhance the understanding of the mechanism of efficacy for current atypical antipsychotics. Although the 5-HT 6 receptor is a topical target for schizophrenia, this will not be addressed in this manuscript as we have previously shown that a selective 5-HT 6 receptor antagonist can successfully reverse the PCP-induced deficit in our laboratory . Experiments were carried out using the partial 5-HT 1A receptor agonist, buspirone, alone and in combination with the selective 5-HT 1A receptor antagonist, WAY-100635. We also investigated the effect of the selective 5-HT 2C receptor antagonist, SB-243213A, and the 5-HT 7 receptor antagonist SB-269970A.
Materials and methods

Subjects and housing conditions
Two cohorts of 50 female hooded Lister rats (Harlan, UK) housed in groups of four to five were used as subjects. Animals initially weighing 200-220 g were maintained under standard laboratory conditions at a temperature of 21°C (±2°C) and humidity of 40-50%. They were maintained on a 12-h light/dark cycle (lights on at 0700 hours), and training and testing were carried out between 0830 and 1630 hours. Prior to operant training and testing, rats were gradually food-deprived to approximately 90% of freefeeding body weight; reduced body weight was maintained by restricting the amount of food (standard laboratory chow, Special Diet Services, Essex, UK) given to each rat per day (12 g/day). The availability of water was not restricted. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act UK (1986) and approved by the University of Bradford ethical review process.
Apparatus
All rats were tested in one of eight operant chambers (constructed in-house). Each chamber (29×30×30 cm) consisted of Plexiglas walls and ceiling and a metal grid floor over sawdust. A hinged Plexiglas panel (6×6 cm) provided access to a food hopper containing food pellets (45 mg Noyes pellets, Sandown Scientific, UK). Two retractable levers (4×2 cm) were positioned on either side of the food hopper. A light emitting diode (LED) was positioned centrally above each lever and a house light was located in the ceiling of each chamber. The chambers were placed individually within ventilated sound-attenuating hardboard boxes (69×38×42 cm) containing a Perspex window to allow viewing. A small fan was built into each chamber to mask external noise. Each animal was tested in the same operant chamber throughout the study. All boxes were controlled by Med-PC software (Version 2.0 for DOS or Med-PC for Windows, Med Associates, Inc. Lafayette, IN, USA). Programs were written using Medstate notation.
Operant training sessions
Following habituation to the operant chambers, rats were trained to respond for food on a fixed ratio 1 schedule of reinforcement with both levers active, as previously described in detail (Abdul-Monim et al. 2003 , 2006 . When responding stabilized, rats were trained to press either the left or right lever for food delivery according to a visual cue (LED on or off). The position of the LED to the active lever did not change within the session. The experimental session was terminated following a total of 128 lever presses, which took approximately 30 min. Rats were trained once daily and this was repeated until rats had reached criterion, i.e., 90% correct responding for three consecutive days, and this took approximately 6 weeks of training, 5 days per week.
Reversal learning task
The day before each reversal task session, a full 30-min operant training session (as described above) was conducted in order to ensure stable responding, i.e., 90% correct responding. The reversal learning session involved animals being first exposed to a 5-min period during which the active lever was the same as on the previous operant training day. During this period, responses on both correct and incorrect levers were recorded. This part of the session was termed the initial phase. This was followed by a 2-min time-out period, which was signaled by the house light being turned off. In the subsequent 5-min period, the active lever was reversed. Responses made on the correct and incorrect levers were again recorded. This second period was termed the reversal phase. Animals undertook several of these reversal learning sessions before beginning the drug studies in order to ensure that they attained a stable level of performance, i.e., 90% correct responding and at least 25 lever presses in total, in both the initial and reversal phases of the task. This process took approximately 6 weeks of training, 5 days per week. In both training phases, all rats achieved training criterion within 5 days of each other.
Experimental design-drug studies
Eight to ten trained rats were used per group in the drug studies. Rats were tested on a cycle of 4 days (previously described by Idris et al. 2005, see Table 1 ). On day 1, each animal had a 30-min operant training session. The following day animals received the appropriate drug(s) and undertook a reversal learning test session. On days 3 and 4, each animal underwent a further operant training session and reversal test session, respectively, in order to ensure that responding was regained after the drug treatment. In the current experiments, normal responding was restored following each drug treatment; if performance was not fully restored, the cycle shown in Table 1 would be repeated with no drug treatments until baseline performance in the reversal test was restored.
A total of four drug experiments were carried out using two cohorts of 50 rats. The first cohort was only used for the first drug experiment (SB-269970A). The second cohort took part in the other three experiments. The experiment with buspirone and WAY-100635 was carried out over two experiments; subsequently, the data were pooled giving 20 rats in the vehicle and PCP groups. The drug treatment given to each rat (and within each home cage) over the course of these experiments was randomized. Every effort was made to keep the number of drug and vehicle treatments equivalent among animals and to randomize the order of treatments. The order of procedures and drug treatments is shown as weeks post-training in Table 2 .
Drugs
The doses of buspirone were selected based on previous dose-response experiments carried out in this reversal learning task (McLean et al. 2008b ). WAY-100635 has selective 5-HT 1A receptor antagonist activity at the doses used in this study (Prinssen et al. 1999) . The doses of SB-269970A were selected based on pharmacokinetic analysis (Hagan et al. 2000) , and doses of SB-243213A (5-methyl-1- [[2-[92-methyl-3-pyridyl0oxy ]-5-pyridyl]carbamoyl]-6-trifluoromethylindone hydrochloride) were selected based on effects observed in a study by Wood et al. (2001) .
For both cohorts, the study design involved five groups (n=10 per group initially); following stable performance in The cycle repeated as needed Table 1 The experimental design for each drug study the reversal learning task, rats were given either 2.0 mg/kg PCP (n= 40) or vehicle (0.9% saline; n= 10) by the intraperitoneal (i.p.) route twice daily for 7 days. Dosing with sub-chronic PCP or vehicle was followed by a washout period for a further 7 days. PCP hydrochloride (Sigma, UK) was dissolved in 0.9% saline. This dosage regime has proven to be very successful in our laboratory in producing robust reversal learning (Abdul-Monim et al. 2006 McLean et al. 2009 ), object recognition (Grayson et al. 2007 ) and attentional set-shifting deficits (McLean et al. 2008a) , and social behavior deficits (Snigdha and Neill 2008a, b) . In these experiments, we have used female rats and we have previously shown that the stage of oestrous cycle does not affect reversal learning performance (McLean et al. 2009 ). We have also found females to be better at novel object recognition compared with males (Sutcliffe et al. 2007 ), and we have demonstrated that female rats are more sensitive to our PCP dosage regime in attentional set-shifting (McLean et al. 2007 ). SB-269970A (supplied by GSK, Harlow, UK) was prepared in distilled water and given in a volume of 1 ml/kg via the i.p. route and was administered 45 min before testing. Buspirone hydrochloride (Sigma) and WAY-100635 (Sigma) were dissolved in 0.9% saline and given in 1 ml/kg volume via the i.p. route; buspirone was administered 30 min prior to testing and WAY-100635 was administered 30 min prior to buspirone. In the experiment with WAY-100635 alone, doses of 0.3 and 1.0 mg/kg were administered 30 min prior to testing. SB-243213A (supplied by GSK) was dissolved in vehicle containing cyclodextrin (8% by weight) plus 25 mM citric acid and was administered 30 min prior to testing via the i.p. route in a volume of 2 ml/kg.
Data and statistical analysis
Data for percentage correct responding were calculated using the number of presses on the correct lever divided by the total number of presses multiplied by 100. The percent correct data were then arcsine-transformed and analyzed by a one-way ANOVA followed by post hoc Dunnett's t test comparing drug treatment to the PCP-treated group. The total number of lever presses was calculated by adding the correct and incorrect presses together within the 5-min test session, and this was used to assess whether drugs had caused any sedation or motor impairments.
Results
Experiment 1-effect of SB-269970A
There was no significant effect on total lever pressing in the initial or reversal phases, suggesting that neither locomotor capacity nor motivation was affected (Fig. 1a) . For percent correct responding, a paired t test showed a significant reduction in responding in the reversal phase compared to the initial phase in the PCP-treated group (P<0.001). A one-way ANOVA in the reversal phase showed a significant effect of treatment (F 4, 43 =5.94, P<0.01). Post hoc analysis revealed that SB-269970A at 3 and 10 mg/kg significantly (P<0.01) improved the PCP-induced deficit (Fig. 1b) .
Experiment 2-effect of SB-243213A
There was no significant effect on total lever pressing in the initial or reversal phases, suggesting that neither locomotor capacity nor motivation was affected (Fig. 2a) . For percent correct responding, a paired t test showed a significant reduction in correct responding in the reversal phase compared to the initial phase in the PCP-treated group (P<0.001), 1.0-mg/kg-treated group (P<0.01), and 3.0-mg/ kg-treated group (P<0.001). A one-way ANOVA in the reversal phase showed a significant effect of treatment (F 4, 49 =7.27, P<0.001). Post hoc analysis revealed that SB-243213A at 10 mg/kg significantly (P<0.05) improved the PCP-induced deficit (Fig. 2b) .
Experiment 3-effect of buspirone and WAY-100635
There was no significant effect on total lever pressing in the initial or reversal phases following any acute drug treatment (Fig. 3a) . For percent correct responding, a paired t test showed a significant reduction in correct responding in the reversal phase compared to the initial phase in the PCPtreated group (P<0.001) and in the PCP animals treated acutely with buspirone at 0.15625 mg/kg (P<0.05). A oneway ANOVA in the reversal phase showed a significant effect of treatment (F 6, 75 =5.77, P<0.001). Post hoc analysis revealed that PCP rats treated with buspirone at 0.3125 and 0.625 mg/kg had significantly improved reversal learning compared to the PCP alone group (P<0.01; Fig. 3b ). The lower dose of 0.156 mg/kg had no effect as indicated by a significant reduction in responding compared with the initial phase. Pretreatment with WAY-100635 (0.3 and 1.0 mg/kg) partially antagonized the effect of buspirone (0.3125 mg/kg) such that buspirone in the presence of WAY-100635 (0.3 and 1.0 mg/kg) did not significantly reverse the PCP-induced deficit (P=0.208 and P=0.082, respectively). However, there was no significant difference between buspirone alone (0.3125 mg/kg) and buspirone (0.3125 mg/kg) in the presence of WAY-100635 at 0.3 mg/kg (P=0.451) and 1.0 mg/kg (P=0.712).
Experiment 4-effect of WAY-100635 alone
There was no significant effect on total lever pressing in the initial or reversal phases following treatment with WAY-100635 (Fig. 4a) . For percent correct responding, a paired t test showed a significant reduction in performance of the reversal phase compared with the initial phase in the PCP group (P<0.001) and both WAY-1000635-treated groups (P<0.05, Fig. 4b) . A one-way ANOVA in the reversal phase showed a significant effect of treatment (F 3, 33 =4.57, P<0.01). Post hoc analysis revealed that WAY-100635 at 0.3 and 1.0 mg/kg did not significantly improve correct responding compared to PCP alone in the reversal phase (P=0.54 and P=0.42, respectively).
Discussion
The current experiments utilized an operant reversal learning paradigm to examine the role of specific 5-HT receptor subtypes, namely: 5-HT 7 , 5-HT 2C , and 5-HT 1A receptors in overcoming cognitive impairments due to Nmethyl-D-aspartate (NMDA) receptor antagonism. The principal findings show that the 5-HT 7 receptor antagonist SB-269970A, the 5-HT 2C receptor antagonist SB-243213A, and the 5-HT 1A receptor partial agonist buspirone attenuated the sub-chronic PCP-induced deficit in the reversal phase of the task.
Reversal learning task and PCP-induced disruption
Successful reversal learning ability relies on the intact function of the prefrontal cortex. It has been shown more specifically that lesions of the orbital prefrontal cortex impair reversal learning ability (McAlonan and Brown 2003; Tait and Brown 2007) . The prefrontal cortex is believed to be important for effective functioning in tests such as the Wisconsin Card Sorting Test and impaired performance is seen in patients with schizophrenia (Haut et al. 1996; Pantelis et al. 1999) . It has been shown that 5-HT receptor antagonists could have antipsychotic efficacy via increasing release of dopamine in the PFC (Ichikawa and Meltzer 1990; Di Matteo et al. 2001) . PCP has been shown to affect dopamine levels within the PFC and nucleus accumbens, and reduced dopamine within the PFC is thought to mediate both negative and cognitive symptoms of schizophrenia (Jentsch and Roth 1999) ; thus, the activity at 5-HT receptors may indirectly improve PCP-induced deficits via modulation of dopamine release in the PFC. In a recent novel object recognition study, we have shown that sub-chronic PCP impairs the ability of rats to recognize the familiar object in retention (and hence discriminate between the novel and familiar object) and also abolishes prefrontal dopamine release which is increased in control rats selectively in the retention trial (Snigdha et al. 2008c ). Moreover, we have recently shown that the dopamine D 1 receptor agonist, SKF-38393, improves sub-chronic PCPinduced deficits in reversal learning and novel object recognition (McLean et al. 2009 ). These findings strongly support a role for prefrontal dopamine working through a D 1 receptor mechanism to improve cognition of relevance to schizophrenia. The present results show that vehicle-treated rats can be trained to an equivalent level of accuracy in both the initial and reversal phases of the task. Following treatment with sub-chronic PCP, rats demonstrated a robust and replicable impairment which is selective for the reversal phase. We 
Effect of SB-269970A
SB-269970A is a selective 5-HT 7 receptor antagonist (Varnäs et al. 2004) . 5-HT 7 receptors are located in the thalamus, hypothalamus, and amygdala in addition to limbic and cortical regions (Thomas et al. 2002; Varnäs et al. 2004 ). Activity at 5-HT 7 receptors has been suggested to have a strong role in cognitive dysfunction (Hedlund and Sutcliffe 2004; Thomas and Hagan 2004) . The 5-HT 7 receptor is a potential target of relevance to schizophrenia as many atypical antipsychotics such as risperidone and ziprasidone have affinity for this receptor (Roth et al. 1994; Siegfried et al. 2001) , and some, e.g., clozapine, have significant inverse agonist activity (Mahe et al. 2004) . The results of experiment 1 with SB-269970A showed that 3.0 and 10.0 mg/kg of SB-269970A significantly ameliorated the PCP-induced deficit. There were no effects on the initial phase of the task or on total lever pressing. SB-269970 (at 3.0 and 10.0 mg/kg) has been previously shown to reverse cognitive impairments induced by scopolamine and dizocilpine (Meneses 2004) . In a recent study by Galici et al. (2008) , SB-269970 (10 and 30 mg/kg) significantly antagonized both amphetamine and ketamineinduced hyperactivity in mice; in addition to this, the effect on amphetamine-induced hyperactivity was not observed in 5-HT 7 knock-out mice, suggesting that SB-269970 has good selectivity for the 5-HT 7 receptor. However, SB-269970 did not block ketamine-induced deficits in prepulse inhibition (PPI; Galici et al. 2008) . PCP-induced deficits in PPI were reversed by SB-258741, an analog of SB-269970 (Pouzet et al. 2002) . Conversely, in a more recent study, it was shown that SB-269970 at 10 mg/kg did not reverse PCP-induced deficits in PPI (Semenova et al. 2008) . Therefore, there are conflicting results surrounding the effect of SB-269970 against PCP-induced deficits in PPI; however, we have demonstrated that SB-269970 at 3 and 10 mg/kg significantly reverses our sub-chronic PCPinduced deficits in a reversal learning task of relevance to schizophrenia, thus strengthening the argument for its importance in therapy of cognition in schizophrenia. It has been hypothesized that 5-HT 7 receptor antagonists may reverse PCP-induced deficits via the prevention of 5-HT and/or glutamate release (Semenova et al. 2008) . However, more research is needed to elucidate the cognitiveenhancing mechanisms of 5-HT 7 receptor antagonists.
Effect of SB-243213A
SB-243213A is a selective 5-HT 2C receptor antagonist (Bromidge et al. 2000) . 5-HT 2C receptors are located in a variety of brain regions including the neocortex, amygdala, hippocampus, nucleus accumbens, substantia nigra, and the ventral tegmental area (Pompeiano et al. 1994; Abramowski et al. 1995; Eberle-Wang et al. 1997 ). Antagonism at 5-HT 2C receptors by various atypical antipsychotics (e.g., clozapine, risperidone, sertindole, and ziprasidone; Roth et al. 2003) may play a role in their beneficial effects and their improved adverse effects profile (Meltzer 1995 (Meltzer , 1999 . However, antagonism at the 5-HT 2C receptor can increase food intake and body weight in rats (Bonhaus et al. 1997 ); thus, this may not be an advantageous strategy for treatment in patients as weight gain is a major adverse effect and could affect compliance (see Allison et al. 1999 for meta-analysis). SB-243213A is active in preclinical models of anxiety and has an improved anxiolytic profile compared with benzodiazepines (Wood et al. 2001; Blackburn et al. 2002) . SB-243213A may also have antidepressant-like activity as it increased deep slow wave sleep quantity with similar effect to paroxetine (Smith et al. 2002) . There is limited data concerning the efficacy of SB-243213A in tests of cognition. The current data show that SB-243213A at 10.0 mg/kg selectively and significantly improved the PCPinduced deficit in the reversal phase of the task, i.e., there were no effects on the initial phase or on total lever pressing. This is supported by recent data showing improvements in spatial reversal learning by the 5-HT 2C antagonist, SB242084 (Boulougouris et al. 2008) , suggesting that the facilitatory effects of 5-HT 2C antagonists could be mediated by the orbitofrontal cortex (OFC) as this task (Boulougouris et al. 2007 ) and reversal learning within the attentional set-shifting task (McAlonan and Brown 2003) have been shown to be dependent on the OFC. The mechanism of the observed cognitive enhancement may be via increasing dopamine in the PFC. 5-HT 2C receptor Reversal phase Fig. 4 The influence of WAY-100635 (0.3 and 1.0 mg/kg, i.p.) alone on the effect of subchronic PCP on performance of the initial and reversal phase of the reversal learning task (n=8-10). activation has been suggested to reduce dopamine release in the nucleus accumbens and prefrontal cortex (Di Matteo et al. 2001 ). The 5-HT 2C antagonist, SB242084, enhances dopamine release in the nucleus accumbens (Di Matteo et al. 1999 ) and cortex (Gobert et al. 2000) .
Effect of buspirone and WAY-100635
In the current study, the efficacy of buspirone to improve the PCP-induced reversal learning deficit was antagonized partially by the 5-HT 1A antagonist, WAY-100635. There is evidence that 5-HT 1A receptor density is abnormally high in the frontal cortices of patients with schizophrenia (Burnet et al. 1997 ) and a subsequent positron emission tomography study has shown an increase in cortical 5-HT 1A receptor binding in schizophrenia (Tauscher et al. 2002) . Postmortem studies have also indicated abnormalities in 5-HT 1A receptor-mediated transmission in the frontal cortex of patients with schizophrenia (Sumiyoshi et al. 1996) . Buspirone is a 5-HT 1A receptor partial agonist with weak D 2 receptor antagonist properties compared to typical antipsychotic drugs, with Ki values of 20 and 240 nM, respectively (Hamik et al. 1990 ). WAY-100635 may not have fully antagonized the effects of buspirone as it is rapidly converted to its metabolite 1-(2-pyrimidinyl)-piperazine (Caccia et al. 1986 ), a potent α 2 -adrenoceptor antagonist, which is able to stimulate cortical dopamine release (Gobert et al. 1999) . The effect of buspirone cannot be due to D 2 blockade as haloperidol is ineffective in reversing the PCPinduced deficit (Abdul-Monim et al. 2006) .
It is important to highlight that WAY-100635 administered alone at both 0.3 and 1.0 mg/kg did not improve the PCP-induced deficit. This is in agreement with a study in mice using a novel object recognition task whereby WAY-100635 at 1.0 mg/kg did not produce any improvement in the PCP-induced cognitive deficit (Hagiwara et al. 2008) . However, there are conflicting results surrounding the effects of WAY-100635 and other 5-HT 1A receptor antagonists; Wedzony et al. (2000) reported that WAY-100135 attenuated the deficit induced by MK-801 in tests of working memory and selective attention in rats. In addition, WAY-100635 has been shown to prevent learning deficits induced by blockade of AMPA receptors (Schiapparelli et al. 2006 ). An explanation for the conflicting effects of WAY-100635 and WAY-100135 could be due to the acute administration of MK-801 (an NMDA receptor antagonist) and NBQX (an AMPA receptor antagonist) in comparison to our sub-chronic PCP administration, and also, the aforementioned studies were performed in male Wistar rats compared to our female hooded Lister rats.
The antipsychotics clozapine, quetiapine, and ziprasidone have partial agonist properties at 5-HT 1A receptors, like buspirone (Newman-Tancredi et al. 1998; Ichikawa et al. 2001 ). There are conflicting preclinical results with 5-HT 1A compounds with selective agonists, partial agonists, and antagonists all being highlighted as potential molecular targets for cognitive enhancement in schizophrenia (see Gray and Roth 2007) . As previously mentioned, there is a high concentration of 5-HT 1A receptors on cortical and hippocampal pyramidal neurons (Azmitia et al. 1996) . There is also a population of 5-HT 1A receptors on raphe neurons, where 5-HT 1A receptors function as somatodendritic autoreceptors providing inhibitory feedback control of 5-HT release (Barnes and Sharp 1999) . It is thought that this is where the action of 5-HT 1A antagonists is seen to improve cognition, while the beneficial effects on cognition in animal studies of 5-HT 1A partial agonists are thought to be mediated via an action at pyramidal neurons Schechter et al. 2002) . In schizophrenic patients, the 5-HT 1A agonist, tandospirone, has been shown to improve executive function and verbal memory when added on to ongoing typical antipsychotic treatment (Sumiyoshi et al. 2001) .
Our results from the present study are supported by another investigation from our laboratory in a social interaction test (Snigdha and Neill 2008a) . It was demonstrated that co-administration of WAY-100635 with aripiprazole, a partial 5-HT 1A agonist (Shapiro et al. 2003) , successfully prevented the beneficial effects of aripiprazole in a social interaction model of negative symptoms. It was suggested that 5-HT 1A receptor activation selectively augments cortical dopamine levels which results in improvement in the social behavior deficits. This suggestion is in agreement with a previous report by Ichikawa et al. (2001) suggesting that 5-HT 1A -induced dopamine release in the mPFC may be the potential basis for the mechanism of action of at least some of the atypical antipsychotics. Our previous results showing impaired cortical dopamine release in PCP-treated rats supports this hypothesis.
Conclusions
Sub-chronic PCP induces a robust reversal learning deficit, which is selective for the reversal phase of the reversal learning task; this is of great relevance for cognition in schizophrenia and this paradigm is listed by TURNS as a relevant task. SB-269970A, SB-243213A, and buspirone attenuated the PCP-induced deficit, with WAY-100635 partially antagonizing the effect of buspirone. We have also demonstrated that when administered alone WAY-100635 did not improve the PCP-induced cognitive deficit. The current studies suggest possible mechanisms of action of antipsychotics and particularly implicate the role of 5-HT 7 , 5-HT 2C , and 5-HT 1A receptors in the improvement of cognitive dysfunction of relevance to schizophrenia.
